新型盐酸艾司洛尔外用药 3 期研究中患者和伤口特征对糖尿病足溃疡愈合的影响

IF 0.7 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM International Journal of Diabetes in Developing Countries Pub Date : 2024-04-15 DOI:10.1007/s13410-024-01336-2
Ashu Rastogi, Raveena Singh, Umanath Adhikari, Sudhir A. Kulkarni, Supreet K. Deshpande
{"title":"新型盐酸艾司洛尔外用药 3 期研究中患者和伤口特征对糖尿病足溃疡愈合的影响","authors":"Ashu Rastogi, Raveena Singh, Umanath Adhikari, Sudhir A. Kulkarni, Supreet K. Deshpande","doi":"10.1007/s13410-024-01336-2","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Novel topical esmolol is shown to significantly improve wound healing than standard of care. Certain patient-related factors especially anemia and poor glycemic control may impede wound healing.</p><h3 data-test=\"abstract-sub-heading\">Objective</h3><p>To study whether novel topical esmolol may circumvent patient-related factors to improve wound healing in diabetic foot ulcer (DFU).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The present study is a double-blind, vehicle (placebo)-controlled, randomized clinical trial in subjects with non-infected DFU of University of Texas grade 1A and 1C. Participants were randomized to receive either topical esmolol gel (Galnobax) with standard of care (SoC), SoC only, and vehicle (Placebo) with SoC in 3:3:1 proportion. The hematologic and biochemistry parameters were evaluated at the screening visit and at every 4 weeks after randomization during treatment phase and at the end of the study (EOS). Outcome was the proportion of complete ulcer closure with reference to baseline hemoglobin, albumin, and HbA1c during the 12-week treatment phase.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 176 subjects were included. Ninety-four out of 140 participants (67.1%) had anemia at baseline. Among anemic participants, 57.4% ulcers closed in the Galnobax group whereas 42.6% closed in the SoC only group during the 12-week treatment phase (<i>p</i> = 0.148, OR = 1.823, 95% CI = 0.80–4.13). One-third participants reported albumin &lt; 4.0 g/dL. Among participants having albumin &lt; 4.0 g/dL (one-third of participants), the proportion of ulcer closure was 60.9% in the Galnobax group compared to 42.1% in the SoC only group (<i>p</i> = 0.225, OR = 2.139, 95% CI = 0.62–7.37). The proportion of ulcer closure in Galnobax with the SoC group was higher (72.5%) compared to the SoC only group (43.5%) (<i>p</i> = 0.0067, OR = 3.427, 95% CI = 1.38–8.48) in participants with poor glycemic control (HbA1c &gt; 8%).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Novel topical esmolol with SoC treatment exhibited significant DFU healing independent of patient-related factors including anemia, hypoalbuminemia, and poor glycemic control.</p>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of patient and wound characteristics on diabetic foot ulcer healing in phase 3 study of novel topical esmolol hydrochloride\",\"authors\":\"Ashu Rastogi, Raveena Singh, Umanath Adhikari, Sudhir A. Kulkarni, Supreet K. Deshpande\",\"doi\":\"10.1007/s13410-024-01336-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Background</h3><p>Novel topical esmolol is shown to significantly improve wound healing than standard of care. Certain patient-related factors especially anemia and poor glycemic control may impede wound healing.</p><h3 data-test=\\\"abstract-sub-heading\\\">Objective</h3><p>To study whether novel topical esmolol may circumvent patient-related factors to improve wound healing in diabetic foot ulcer (DFU).</p><h3 data-test=\\\"abstract-sub-heading\\\">Methods</h3><p>The present study is a double-blind, vehicle (placebo)-controlled, randomized clinical trial in subjects with non-infected DFU of University of Texas grade 1A and 1C. Participants were randomized to receive either topical esmolol gel (Galnobax) with standard of care (SoC), SoC only, and vehicle (Placebo) with SoC in 3:3:1 proportion. The hematologic and biochemistry parameters were evaluated at the screening visit and at every 4 weeks after randomization during treatment phase and at the end of the study (EOS). Outcome was the proportion of complete ulcer closure with reference to baseline hemoglobin, albumin, and HbA1c during the 12-week treatment phase.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>A total of 176 subjects were included. Ninety-four out of 140 participants (67.1%) had anemia at baseline. Among anemic participants, 57.4% ulcers closed in the Galnobax group whereas 42.6% closed in the SoC only group during the 12-week treatment phase (<i>p</i> = 0.148, OR = 1.823, 95% CI = 0.80–4.13). One-third participants reported albumin &lt; 4.0 g/dL. Among participants having albumin &lt; 4.0 g/dL (one-third of participants), the proportion of ulcer closure was 60.9% in the Galnobax group compared to 42.1% in the SoC only group (<i>p</i> = 0.225, OR = 2.139, 95% CI = 0.62–7.37). The proportion of ulcer closure in Galnobax with the SoC group was higher (72.5%) compared to the SoC only group (43.5%) (<i>p</i> = 0.0067, OR = 3.427, 95% CI = 1.38–8.48) in participants with poor glycemic control (HbA1c &gt; 8%).</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusions</h3><p>Novel topical esmolol with SoC treatment exhibited significant DFU healing independent of patient-related factors including anemia, hypoalbuminemia, and poor glycemic control.</p>\",\"PeriodicalId\":50328,\"journal\":{\"name\":\"International Journal of Diabetes in Developing Countries\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Diabetes in Developing Countries\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13410-024-01336-2\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Diabetes in Developing Countries","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13410-024-01336-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景新型外用艾司洛尔比标准护理能明显改善伤口愈合。本研究是一项双盲、载体(安慰剂)对照、随机临床试验,受试者为德克萨斯大学 1A 级和 1C 级非感染性 DFU 患者。受试者按 3:3:1 的比例随机接受外用艾司洛尔凝胶(Galnobax)与标准疗法(SoC)、仅接受标准疗法、载体(安慰剂)与标准疗法。血液学和生化指标在筛查时进行评估,并在治疗阶段和研究结束(EOS)时在随机分组后每 4 周进行一次评估。结果 在为期 12 周的治疗阶段,参照基线血红蛋白、白蛋白和 HbA1c,得出溃疡完全闭合的比例。140 名受试者中有 94 人(67.1%)在基线时患有贫血。在贫血参与者中,Galnobax 组有 57.4% 的溃疡在 12 周治疗阶段愈合,而仅 SoC 组有 42.6% 的溃疡在 12 周治疗阶段愈合(P = 0.148,OR = 1.823,95% CI = 0.80-4.13)。三分之一的参与者报告白蛋白大于等于 4.0 g/dL。在白蛋白大于等于 4.0 g/dL 的参与者(占三分之一)中,Galnobax 组的溃疡闭合比例为 60.9%,而仅使用 SoC 组为 42.1%(p = 0.225,OR = 2.139,95% CI = 0.62-7.37)。在血糖控制不佳(HbA1c >8%)的参与者中,Galnobax 与 SoC 组的溃疡闭合比例(72.5%)高于仅 SoC 组(43.5%)(p = 0.0067,OR = 3.427,95% CI = 1.38-8.48)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Effect of patient and wound characteristics on diabetic foot ulcer healing in phase 3 study of novel topical esmolol hydrochloride

Background

Novel topical esmolol is shown to significantly improve wound healing than standard of care. Certain patient-related factors especially anemia and poor glycemic control may impede wound healing.

Objective

To study whether novel topical esmolol may circumvent patient-related factors to improve wound healing in diabetic foot ulcer (DFU).

Methods

The present study is a double-blind, vehicle (placebo)-controlled, randomized clinical trial in subjects with non-infected DFU of University of Texas grade 1A and 1C. Participants were randomized to receive either topical esmolol gel (Galnobax) with standard of care (SoC), SoC only, and vehicle (Placebo) with SoC in 3:3:1 proportion. The hematologic and biochemistry parameters were evaluated at the screening visit and at every 4 weeks after randomization during treatment phase and at the end of the study (EOS). Outcome was the proportion of complete ulcer closure with reference to baseline hemoglobin, albumin, and HbA1c during the 12-week treatment phase.

Results

A total of 176 subjects were included. Ninety-four out of 140 participants (67.1%) had anemia at baseline. Among anemic participants, 57.4% ulcers closed in the Galnobax group whereas 42.6% closed in the SoC only group during the 12-week treatment phase (p = 0.148, OR = 1.823, 95% CI = 0.80–4.13). One-third participants reported albumin < 4.0 g/dL. Among participants having albumin < 4.0 g/dL (one-third of participants), the proportion of ulcer closure was 60.9% in the Galnobax group compared to 42.1% in the SoC only group (p = 0.225, OR = 2.139, 95% CI = 0.62–7.37). The proportion of ulcer closure in Galnobax with the SoC group was higher (72.5%) compared to the SoC only group (43.5%) (p = 0.0067, OR = 3.427, 95% CI = 1.38–8.48) in participants with poor glycemic control (HbA1c > 8%).

Conclusions

Novel topical esmolol with SoC treatment exhibited significant DFU healing independent of patient-related factors including anemia, hypoalbuminemia, and poor glycemic control.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
109
审稿时长
6 months
期刊介绍: International Journal of Diabetes in Developing Countries is the official journal of Research Society for the Study of Diabetes in India. This is a peer reviewed journal and targets a readership consisting of clinicians, research workers, paramedical personnel, nutritionists and health care personnel working in the field of diabetes. Original research articles focusing on clinical and patient care issues including newer therapies and technologies as well as basic science issues in this field are considered for publication in the journal. Systematic reviews of interest to the above group of readers are also accepted.
期刊最新文献
Prevalence of obesity and cardiometabolic risk factors among Alavi Bohra adult women Enhancing comprehensive diabetic care: A smartphone fundus camera with an offline AI-powered diabetic retinopathy screening solution for physicians Usefulness of sudomotor function assessment in individuals with type-2 diabetes: A case–control study The effect of high-concentration CO2-enriched water on sensory neuropathy in patients with diabetes referred to an endocrine clinic Clinical profile of monogenic diabetes: A case series from a single South Indian diabetes clinic
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1